Durham drug developer Chimerix reports drop in revenue in 4th quarter

Posted by David Bracken on March 7, 2014 

Antiviral drug developer Chimerix reported a drop in revenue in the fourth quarter because of reduced reimbursements from a federal contract.

The Durham company’s revenue totaled $879,000, compared with $3.6 million during the four quarter of last year. The consensus among Wall Street analysts who cover the company was revenue of $1.2 million.

Chimerix said the drop was largely the result of a decrease in reimbursable expenses related to its contract with the Biomedical Advanced Research and Development Authority, a division of the U.S. Department of Health and Human Services.

Chimerix had a net loss of $8.2 million, or 31 cents per share, in the fourth quarter compared with a net loss of $4.3 million, or $3.90 per share in the same period in 2012. Analysts had forecast a loss of $10 million and 36 cents per share.

Chimerix has no drugs on the market but several in the pipeline. The 54-employee company is developing a treatment for life-threatening viral infections in patients whose immune systems have been compromised by cancer or drugs. Its most advanced experimental drug, brincidofovir, is enrolling patients in Phase 3 clinical trials. Results from the trials are expected next year. Chimerix is also working with BARDA to develop brincidofovir as a medical countermeasure against smallpox.

“2014 will be a year in which we seek to expand the development of brincidofovir into a broader range of DNA viruses, new patient populations and additional territories,” CEO Kenneth Moch said on a conference call with analysts Friday. The company also is looking to plan its activities in Europe this year, Moch said.

Chimerix’s administrative expenses increased from $1.4 million to $2.6 million. The increase was attributed to the added costs of operating as a publicly traded company. Chimerix raised $117.9 million in April in an initial public offering of stock.

For the year, Chimerix reported a net loss of $36.4 million, or $3.65 per share, compared with a net loss of $4.4 million, or $5.75 per share in 2012.

Chimerix shares closed Friday at $18.73, down 17 cents. The shares began trading at $14 in April.

Staff writer David Bracken

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service